Citius Phar­ma­ceu­ti­cals looks to re­file for­mer Ei­sai can­cer drug in ear­ly 2024

Citius Phar­ma­ceu­ti­cals plans to re­file its ex­per­i­men­tal drug for a rare blood can­cer in ear­ly 2024 fol­low­ing an FDA re­jec­tion in Ju­ly.

The drug, Lym­phir, is a re­for­mu­lat­ed ver­sion of Ei­sai’s cu­ta­neous T-cell lym­phoma (CT­CL) treat­ment On­tak, which was vol­un­tar­i­ly pulled from the US mar­ket in 2014 over man­u­fac­tur­ing is­sues. Citius CEO Leonard Mazur told End­points News on Fri­day that “there’s no re­la­tion­ship” be­tween those is­sues and the FDA’s re­cent com­plete re­sponse let­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER